Sleeping Beauty-baculovirus hybrid vectors for long-term gene expression in the eye

Journal of Gene Medicine

Volumn 16, Issue 1-2, 2014, Pages 40-53

  Turunen, Tytteli Anni Kaarina ^a   Laakkonen, Johanna Päivikki ^a   Alasaarela, Laura ^a   Airenne, Kari Juhani ^a   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Baculovirus; Gene therapy; Hybrid vector; Integrating vector; Sleeping Beauty; Transposon

Indexed keywords

BACULOVIRUS VECTOR; GENOMIC DNA; GREEN FLUORESCENT PROTEIN; PLASMID VECTOR; SLEEPING BEAUTY TRANSPOSON BACULOVIRUS HYBRID VECTOR; TRANSPOSASE; UNCLASSIFIED DRUG; SLEEPING BEAUTY TRANSPOSASE, HUMAN; TRANSPOSON;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL CULTURE; CONTROLLED STUDY; DNA INTEGRATION; EYE; FLOW CYTOMETRY; FOLLOW UP; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION ASSAY; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRANSGENE; TRANSPOSON; ANIMAL; BACULOVIRIDAE; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEPG2 CELL LINE; KNOCKOUT MOUSE; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BACULOVIRIDAE; CELL LINE, TUMOR; DNA TRANSPOSABLE ELEMENTS; EYE; GENE EXPRESSION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEP G2 CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; TRANSDUCTION, GENETIC; TRANSGENES; TRANSPOSASES;

EID: 84894494076     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2756     Document Type: Article

References (62)

1. Szewczyk B, Hoyos-Carvajal L, Paluszek M, Skrzecz I, Lobo De Souza M. Baculoviruses - re-emerging biopesticides. Biotechnol Adv 2006; 24: 143-160.
2. Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 2005; 23: 567-575.
3. Laakkonen JP, Kaikkonen MU, Ronkainen PHA, et al. Baculovirus-mediated immediate-early gene expression and nuclear reorganization in human cells. Cell Microbiol 2008; 10: 667-681.
4. Airenne KJ, Hu Y-C, Kost TA, et al. Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol Ther 2013; 21: 739-749.
5. Hu Y-C. Baculoviral vectors for gene delivery: a review. Curr Gene Ther 2008; 8: 54-65.
6. Haeseleer F, Imanishi Y, Saperstein DA. Gene transfer mediated by recombinant baculovirus into mouse eye. Invest Ophthalmol Vis Sci 2001; 42: 3294-3300.
7. Kinnunen K, Kalesnykas G, Mähönen AJ, et al. Baculovirus is an efficient vector for the transduction of the eye: comparison of baculovirus- and adenovirus-mediated intravitreal vascular endothelial growth factor D gene transfer in the rabbit eye. J Gene Med 2009; 11: 382-389.
8. Lehtolainen P, Tyynelä K, Kannasto J, Airenne KJ, Ylä-Herttuala S. Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo. Gen Ther 2002; 9: 1693-1699.
9. Wang C-Y, Li F, Yang Y, Guo H-Y, Wu C-X, Wang S. Recombinant baculovirus containing the Diphtheria toxin A gene for malignant glioma therapy. Cancer Res 2006; 66: 5798-5806.
10. Tani H, Limn CK, Yap CC, et al. In vitro and In vivo gene delivery by recombinant baculoviruses. J Virol 2003; 77: 9799-9808.
11. Kaikkonen MU, Räty JK, Airenne KJ, Wirth T, Heikura T, Ylä-Herttuala S. Truncated vesicular stomatitis virus G protein improves baculovirus transduction efficiency in vitro and in vivo. Gen Ther 2006; 13: 304-312.
12. Cheshenko N, Krougliak N, Eisensmith RC, Krougliak VA. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Gen Ther 2001; 8: 846-854.
13. Airenne KJ, Peltomaa E, Hytönen VP, Laitinen OH, Ylä-Herttuala S. Improved generation of recombinant baculovirus genomes in Escherichia coli. Nucleic Acids Res 2003; 31: e101.
14. Condreay JP, Witherspoon SM, Clay WC, Kost TA. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci U S A 1999; 96: 127-132.
15. Airenne KJ, Hiltunen MO, Turunen MP, et al. Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery. Gen Ther 2000; 7: 1499-1504.
16. Ivics Z, Hackett PB, Plasterk RH, Izsvák Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997; 91: 501-510.
17. Izsvák Z, Ivics Z, Plasterk RH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 2000; 302: 93-102.
18. Mátés L, Chuah MKL, Belay E, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009; 41: 753-761.
19. Vandendriessche T, Ivics Z, Izsvák Z, Chuah MKL. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 2009; 114: 1461-1468.
20. Williams DA. Sleeping Beauty vector system moves towards human trials in the United States. Mol Ther 2008; 16: 1515-1516.
21. Yant SR, Wu X, Huang Y, Garrison B, Burgess SM, Kay MA. High-resolution genome-wide mapping of rransposon integration in mammals. Mol Cell Biol 2005; 25: 2085-2094.
22. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favoured targets for MLV integration. Science 2003; 300: 1749-1751.
23. Schröder ARW, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favours active genes and local hotspots. Cell 2002; 110: 521-529.
24. Hüser D, Gogol-Döring A, Lutter T, et al. Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog 2010; 6: e1000985.
25. Wilson MH, Coates CJ, George ALJ. PiggyBac Transposon-mediated gene transfer in human cells. Mol Ther 2007; 15: 139-145.
26. Liu G, Geurts AM, Yae K, et al. Target-site preferences of Sleeping Beauty transposons. J Mol Biol 2005; 346: 161-173.
27. Vigdal TJ, Kaufman CD, Izsvák Z, Voytas DF, Ivics Z. Common physical properties of DNA affecting target site selection of Sleeping Beauty and other Tc1/mariner transposable elements. J Mol Biol 2002; 323: 441-452.
28. Airenne KJ, Makkonen K-E, Mähönen AJ, Ylä-Herttuala S. In vivo application and tracking of baculovirus. Curr Gene Ther 2010; 10: 187-194.
29. Chen C-L, Luo W-Y, Lo W-H, et al. Development of hybrid baculovirus vectors for artificial MicroRNA delivery and prolonged gene suppression. Biotechnol Bioeng 2011; 108: 2958-2967.
30. Luo W-Y, Shih Y-S, Hung C-L, et al. Development of the hybrid Sleeping Beauty-baculovirus vector for sustained gene expression and cancer therapy. Gene Ther 2012; 19: 844-851.
31. Kinnunen K, Ylä-Herttuala S. Gene therapy in age related macular degeneration and hereditary macular disorders. Front Biosci (Elite Ed) 2012; 4: 2546-2557.
32. Laitinen OH, Airenne KJ, Hytönen VP, et al. A multipurpose vector system for the screening of libraries in bacteria, insect and mammalian cells and expression in vivo. Nucleic Acids Res 2005; 33: e42.
33. Heikura T, Nieminen T, Roschier MM, et al. Baculovirus-mediated vascular endothelial growth factor-D(ΔNΔC) gene transfer induces angiogenesis in rabbit skeletal muscle. J Gene Med 2012; 14: 35-43.
34. Izsvák Z, Ivics Z. Sleeping Beauty transposition: biology and applications for molecular therapy. Mol Ther 2004; 9: 147-156.
35. Baer M, Nilsen TW, Costigan C, Altman S. Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P. Nucleic Acids Res 1990; 18: 97-103.
36. Applied Biosystems. Creating Standard Curves with Genomic DNA or Plasmid DNA Templates for Use in Quantitative PCR. 2003. http://www6.appliedbiosystems.com/support/tutorials/pdf/quant_pcr.pdf.
37. Soboleski MR, Oaks J, Halford WP. Green fluorescent protein is a quantitative reporter of gene expression in individual eukaryotic cells. FASEB J 2005; 19: 440-442.
38. Ivics Z, Izsvák Z. Nonviral gene delivery with the Sleeping Beauty transposon system. Hum Gene Ther 2011; 22: 1043-1051.
39. Hackett CS, Geurts AM, Hackett PB. Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy. Genome Biol 2007; 8(Suppl 1): S12.
40. Hüser A, Rudolph M, Hofmann C. Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat Biotechnol 2001; 19: 451-455.
41. Kaikkonen MU, Määttä AI, Ylä-Herttuala S, Airenne KJ. Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery. Mol Ther 2010; 18: 987-992.
42. Chuang C-K, Sung L-Y, Hwang S-M, Lo W-H, Chen H-C, Hu Y-C. Baculovirus as a new gene delivery vector for stem cell engineering and bone tissue engineering. Gene Ther 2007; 14: 1417-1424.
43. Sung L-Y, Lo W-H, Chiu H-Y, et al. Modulation of chondrocyte phenotype via baculovirus-mediated growth factor expression. Biomaterials 2007; 28: 3437-3447.
44. Shan L, Wang L, Yin J, Zhong P, Zhong J. An OriP/EBNA-1-based baculovirus vector with prolonged and enhanced transgene expression. J Gene Med 2006; 8: 1400-1406.
45. Lo W-H, Hwang S-M, Chuang C-K, Chen C-Y, Hu Y-C. Development of a hybrid baculoviral vector for sustained transgene expression. Mol Ther 2009; 17: 658-666.
46. Yant SR, Ehrhardt A, Mikkelsen JG, Meuse L, Pham T, Kay MA. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 2002; 20: 999-1005.
47. Bowers WJ, Mastrangelo MA, Howard DF, Southerland HA, Maguire-Zeiss KA, Federoff HJ. Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector. Mol Ther 2006; 13: 580-588.
48. Staunstrup NH, Moldt B, Mátés L, et al. Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol Ther 2009; 17: 1205-1214.
49. Vink CA, Gaspar HB, Gabriel R, et al. Sleeping Beauty transposition from nonintegrating lentivirus. Mol Ther 2009; 17: 1197-1204.
50. Mikkelsen JG, Yant SR, Meuse L, Huang Z, Xu H, Kay MA. Helper-independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Mol Ther 2003; 8: 654-665.
51. Garrison BS, Yant SR, Mikkelsen JG, Kay MA. Postintegrative gene silencing within the Sleeping Beauty transposition system. Mol Cell Biol 2007; 27: 8824-8833.
52. Robert VJP, Sijen T, van Wolfswinkel J. Chromatin and RNAi factors protect the C. elegans germline against repetitive sequences. Genes Dev 2005; 19: 782-787.
53. Bestor TH, Bourc'his D. Transposon silencing and imprint establishment in mammalian germ cells. Cold Spring Harb Symp Quant Biol 2004; 69: 381-387.
54. McBurney MW, Mai T, Yang X, Jardine K. Evidence for repeat-induced gene silencing in cultured mammalian cells: inactivation of tandem repeats of transfected genes. Exp Cell Res 2002; 274: 1-8.
55. Tang W, Newton RJ, Weidner DA. Genetic transformation and gene silencing mediated by multiple copies of a transgene in eastern white pine. J Exp Bot 2007; 58: 545-554.
56. Luz-Madrigal A, Clapp C, Aranda J, Vaca L. In vivo transcriptional targeting into the retinal vasculature using recombinant baculovirus carrying the human flt-1 promoter. Virol J 2007; 4: 88.
57. Feng Y, Lorincz MC, Fiering S, Greally JM, Bouhassira EE. Position effects are influenced by the orientation of a transgene with respect to flanking chromatin. Mol Cell Biol 2001; 21: 298-309.
58. Kolacsek O, Krízsik V, Schamberger A, et al. Reliable transgene-independent method for determining Sleeping Beauty transposon copy numbers. Mob DNA 2011; 2: 5.
59. Johnen S, Izsvák Z, Stöcker M, et al. Sleeping Beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. Invest Ophthalmol Vis Sci 2012; 53: 4787-4796.
60. Nakazawa Y, Saha S, Galvan DL, et al. Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J Immunother 2013; 36: 3-10.
61. Priya RR, Chew EY, Swaroop A. Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management. Ophthalmology 2012; 119: 2526-2536.
62. Simpson E. A historical perspective on immunological privilege. Immunol Rev 2006; 213: 12-22.